Lucence
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
3520 W Bayshore Rd, Palo Alto, Californi...Phone Number
(888) 582-3623Website
www.lucence.comRevenue
$5.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
2
1
1
About Lucence
Founded in 2016, Lucence is a precision oncology company that develops advanced liquid biopsy blood tests that select suitable cancer treatments by molecular profiling. Lucence is headquartered in Singapore.Explore more
Lucence Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lucence your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Lucence launches new products
Earning: See what the market has to say on Lucence recently announced quarterly report
Check out if Lucence is spiking on competitors!
Click to see if Lucence had a recent Job posting/layoffs
Check if Lucence has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Lucence, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Lucence
Funding: Get notified immidiatlly once Lucence has new funding data
Recommended Actions
Reach out to Masked Content who joined Lucence as Masked Content
Find more new buyers
Compare Similar Companies to Lucence
Compare insights from companies similar to Lucence, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$22.2M
51-200
Private
$10M
2015
AD
Alicia DillardAssociate Clinical Laboratory Director and Molecular Pathologist
Company Profile Activity
Activity Insights
Lucence is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Lucence is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Lucence.
Lucence financials insights
Gather financial insights about Lucence, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$20M
Lucence Tech Stack
A closer look at the technologies used by Lucence
Most Recent Scoops
Event
Person-Based
Events, Marketing Strategy, Podcast
Event
Person-Based
IPO, Events, Spending/Investment, Funding, Business Finance, Finance, Financing & Debt, Private Equity, Podcast
Event
Person-Based
Events, Business Finance, Finance, Podcast
Event
Person-Based
Funding, Finance
Hiring Plans
Hiring Plans
Lucence News & Media
Lucence Announces Medicare Reimbursement Decision for LiquidHALLMARK® Assay in Lung Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--Lucence announced today that Palmetto GBA, a Medicare administrative contractor and leader in evaluating molecular diagnostic technology through its laboratory technology assessment group for the Molecular Diagnostics Services program (MolDX), has finalized a foundational Local Coverage Determination (LCD) for the LiquidHALLMARK assay. The LCD covers all nine NCCN guideline-recommended molecular biomarkers in advanced lung cancer patients using LiquidHALLMARKLucence Presents Data at 2022 World Conference on Lung Cancer (WCLC) Supporting Utility of Amplicon-Based Liquid Biopsy From Detection Through Treatment
VIENNA--(BUSINESS WIRE)--Lucence will present new data at the upcoming IASLC 2022 World Conference on Lung Cancer on August 6-9, 2022, highlighting novel applications of its ultrasensitive amplicon-based next generation sequencing technology in the detection and treatment of lung cancer. “Liquid biopsy will continue to transform the way we diagnose, treat, and understand lung cancer,” said Min-Han Tan, Founding CEO and Medical Director at Lucence. “Lucence is committed to leveraging our ultraseLucence Announces Publication of Validation Study for LiquidHALLMARK ctDNA Liquid Biopsy Assay
PALO ALTO, Calif.--(BUSINESS WIRE)--Lucence, the precision oncology company pioneering ultrasensitive liquid biopsy tests, is announcing the recent publication of a study validating its LiquidHALLMARK ctDNA liquid biopsy assay in PLOS ONE, a peer-reviewed, open access scientific journal. The study results establish high sensitivity, specificity, accuracy and precision of LiquidHALLMARK, based on the AmpliMark amplicon-sequencing platform, and support compelling clinical applications for its useLucence’s LiquidHALLMARK Liquid Biopsy Assay Expands to Include cfRNA
PALO ALTO, Calif.--(BUSINESS WIRE)--Lucence, a precision oncology company using liquid biopsy to bring clarity to cancer care, is announcing the availability of an expanded version of its flagship LiquidHALLMARK liquid biopsy assay that includes both cell-free DNA (cfDNA) and cell-free RNA (cfRNA) profiling. LiquidHALLMARK cfDNA and cfRNA is currently available to US oncologists as a laboratory developed test and is being utilized by physicians at NCI-designated centers across the country. Most
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Lucence
Sign Up For FreeTo access detailed company insights
Founded in 2016, Lucence is a precision oncology company that develops advanced liquid biopsy blood tests that select suitable cancer treatments by molecular profiling. Lucence is headquartered in Singapore.... Read More
